GSK Reports EMA’s Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma

 GSK Reports EMA’s Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma

Shots:

  • The MAA is based on DREAMM-2 P-II study (DRiving Excellence in Approaches to Multiple Myeloma) study which involves assessing of Belantamab Mafodotin in heavily pre-treated patients with MM who were refractory to an immunomodulatory drug and a proteasome inhibitor and were refractory and/or intolerant to an anti-CD38Ab
  • The study resulted in 31% ORR with a 2.5 mg/kg regimen of single agent belantamab mafodotin with consistent safety and tolerability profile, published in The Lancet Oncology
  • Belantamab Mafodotin is an anti-B cell maturation antigen (BCMA) mAb conjugated to the cytotoxic agent auristatin F via non-cleavable linker and has been accepted for accelerated assessment by the EMA’s CHMP, also received EMA’s PRIME designation in 2017

Click here to read full press release/ article | Ref: GSK | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post